Alues from baseline to Week 12 in Norwegian individuals with ankylosing spondylitis, stratified as outlined by treatment group (celecoxib 200 or 400 mg day-to-day [qd] or diclofenac 50 mg 3 times each day [tid]): safety population. Celecoxib Parameter C-reactive protein N Abnormal serum chemistry, baseline Abnormal serum chemistry, Week 12 Adjust from baseline to Week 12, mg/l Na Alanine aminotransferase N Abnormal serum chemistry, baseline Abnormal serum chemistry, Week 12 Transform from baseline to Week 12, U/l Na Aspartate aminotransferase N Abnormal serum chemistry, baseline Abnormal serum chemistry, Week 12 Transform from baseline to Week 12, U/l Na 200 mg group 107 31 (29.0) 32 (29.9) 0.8 five.five 99 107 11 (ten.three) 11 (10.3) .7 12.9 98 107 2 (1.9) three (2.eight) .1 7.6 98 400 mg group 108 41 (38.0) 36 (33.3) .three 12.3 102 108 10 (9.three) six (5.six) .eight 11.5 99 108 1 (0.9) 0 (0) .six 5.7 101 Diclofenac group 115 41 (35.7) 36 (31.three) 0.7 8.six 107 115 7 (6.1) 21 (18.3) 9.two 20.0 107 115 two (1.7) 2 (1.7) 2.1 eight.6Data presented as: n or n ( ) individuals; imply SEM (modify from baseline to Week 12). many intention-to-treat sufferers with baseline and Week 12 measures.trial (with only 330 of an anticipated 480 sufferers randomized), statistical consideration from the results was doable across a range of key and secondary measures. The main results of this study indicated that celecoxib, at each 200 mg and 400 mg qd, and diclofenac 50 mg tid, had been effective in treating Norwegian sufferers with AS. No difference was observed involving the two doses of celecoxib versus diclofenac with regards to efficacy. Global Discomfort Intensity decreased similarly in all three treatment groups amongst baseline and Week 12, with no statistically important difference amongst either of your celecoxib groups and the maximum licensed everyday dose of diclofenac.2246363-82-4 uses There had been, however, numerical therapy variations favouring celecoxib 400 mg for some secondary parameters.170097-87-7 In stock Suggestions, ifnot statistical evidence, of incremental efficacy using a total day-to-day dose of 400 mg of celecoxib compared with 200 mg have also been reported in a 12-week trial comparing celecoxib 200 mg qd and 400 mg qd with naproxen 500 mg twice each day (bid),9 and inside a second study comparing 200 mg qd and 200 mg bid with diclofenac slow release 75 mg bid.PMID:26780211 12 In contrast towards the other clinical trial data comparing celecoxib and diclofenac in AS, there was no consistent proof inside the present study that continuous use of NSAIDs over 12 weeks features a lowering impact on levels of CRP. Most trial information for celecoxib and classic NSAIDs suggest that, as a broad class of medicines, NSAIDs minimize CRP within the AS population;80 nonetheless, this contrasts with the findings fromWalker et al. a 24-week study of sufferers with rheumatoid arthritis (RA), which showed approximate two mg/ml increases in CRP with both celecoxib (200 mg bid) and diclofenac (75 mg bid).16 Given that elevated CRP has been postulated to correlate with severity of disease in AS17 and that studies recommend the disease-delaying added benefits might be greatest in patients with raised CRP,13 additional study is warranted to corroborate these findings. The kinds of adverse events most typically reported within this study are consistent using the recognized toxicities of NSAIDs, be they classic or COX-2 selective agents. Overall, there were fewer treatment-emergent adverse events amongst individuals treated with celecoxib than in these treated with diclofenac. The majority of treatmentemergent adverse events.